Outpatient costs of osteoporosis in a national health insurance population

Clinical Therapeutics

Volumn 21, Issue 11, 1999, Pages 2001-2014

  Krappweis, Jutta ^a   Rentsch, Anke ^a   Schwarz, Ute I ^a   Krobot, Karl J ^b   Kirch, Wilhelm ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b MSD Sharp and Dohme GmbH   (Germany)

Author keywords

Cost; Osteoporosis; Prevalence

Indexed keywords

CALCITONIN; CALCIUM ANTAGONIST; FLUORIDE SODIUM; FLUOROPHOSPHATE;

ADULT; AGED; ARTICLE; CALCULATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OUTPATIENT; PREVALENCE; STATISTICAL ANALYSIS; TREATMENT PLANNING;

EID: 0032796434     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)86745-4     Document Type: Note

References (30)

1. 1. Consensus Development Statement. Who are candidates for prevention and treatment for osteoporosis? Osteoporosis Int. 1997;7:1-6.
2. 2. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 1993;94:646-650.
3. 3. Osteoporose: Die Empfehlungen der Deutschen Arbeitsgemeinschaft Osteoporose (DAGO). Klin Pharmakol Aktuell. 1998;9:47-53.
4. 4. Siggelkow H, Hüfner M. Prevention of osteoporosis -Why? Who? How? Med Klin. 1995;90:639-644.
5. 5. Kristiansen IS, Johnell O. Economic and quality of life aspects of osteoporosis. In: Waerstedt A, Roksvaag PO, Beermann B, Strandberg K, eds. Treatment of Osteoporosis. Oslo, Norway: Norwegian Medicines Control Authority; 1997:63-77.
6. 6. Ross PD. Osteoporosis: Frequency, consequences, and risk factors. Arch Intern Med. 1996;156:1399-1411.
7. 7. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Br Med J. 1994;308:1081-1082.
8. 8. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-676.
9. 9. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on the risk of fracture in women with existing vertebral fractures. Lancet. 1996; 348:1535-1541.
10. 10. Liberman UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-1443.
11. 11. World Health Organization. ICD-10: Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme, 10th Revision. Berlin: Springer-Verlag; 1994.
12. 12. Schwabe U. Anatomisch-therapeutisch-chemische Klassifikation für den deutschen Arzneimittelmarkt. Bonn, Germany: Wissenschaftliches Institut der Ortskrankenkassen (WIdO); 1995.
13. 13. Klauber J, Selke GW. Ergänzende statistische Übersicht. In: Schwabe U, Paffrath D, eds. Drug Prescription Report '95. Stuttgart, Germany: Gustav Fischer; 1995: 506-508.
14. 14. Arbeitsgruppe Osteoporose. Empfehlungen zur Prävention, Diagnostik und Therapie der Osteoporose. Wehr, Germany: Ciba Geigy Verlag; 1996.
15. 15. Bottermann P. Modern treatment of primary osteoporosis. Internist. 1994;35:1105-1116.
16. 16. Gruber HE, Ivey IL, Baylink DJ. Long-term calcitonin therapy in post-menopausal osteoporosis. Metabolism. 1984;33:1-10.
17. 17. Haas HG, Liebrich BM, Schaffner W. Calcitonin und Osteoporose - Kritische Durchsicht der Literatur 1980-1989. Klin Wochenschr. 1990;68:359-371.
18. 18. Melton LJ. How many women have osteoporosis now? J Bone Miner Res. 1995; 10:175-177.
19. 19. Meyer HE, Johnell O. Osteoporosis: Epidemiology and risk factors. In: Waerstedt A, Roksvaag PO, Beermann B, Strandberg K, eds. Treatment of Osteoporosis. Oslo, Norway: Norwegian Medicines Control Authority; 1997:45-62.
20. 20. Kann P. Vitamin D and osteoporosis. Dtsch Med Wochenschr. 1994;119:1479-1485.
21. 21. Ringe JD. Osteoporosis in men? Dtsch Med Wochenschr. 1994;119:80-82.
22. 22. Richter K, Lange S. Wirksamkeitsnachweis diagnostischer Massnahmen verbunden mit einer Therapieentscheidung am Beispiel der Osteodensitometrie. In: Braun W, Schaltenbrand R, eds. Pharmakoökonomie. Witten/Herdecke, Germany: Universität Witten/Herdecke Verlagsgesellschaft; 1995: 142-149.
23. 23. Miller PD, Bonnick SL, Rosen CJ. Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. Calcif Tissue Int. 1996; 58:207-214.
24. 24. Ziegler R. What is reliable in the treatment of osteoporosis in menopausal women? Internist. 1993;34:18-24.
25. 25. Harris ST, Watts NB, Jackson RD, et al. Four year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med. 1993;95:557-567.
26. 26. Schwabe U, Paffrath D. Drug Prescription Report '94. Stuttgart, Germany: Gustav Fischer; 1994.
27. 27. Olesen C, Flemming HS, Sørensen HAT, et al. Low use of long-term hormone replacement therapy in Denmark. Br J Clin Pharmacol. 1999;47:323-328.
28. 28. Jolleys IV, Olesen F. A comparative study of prescribing of hormone replacement therapy in USA and Europe. Maturitas. 1996;23:47-53.
29. 29. Griffith F, Jones K. The use of hormone replacement therapy: Results of a community survey. Fam Pract. 1995;12:63-65.
30. 30. Pientka L, Grüger J. Die ökonomische Bë deutung der Osteoporose in Deutschland. Der Kassenarzt. 1996;8:44-52.